Drugs / SHB-02-CD19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07503353 | Jun 2026 → Jun 2029 expected | B-cell non-Hodgkin lymphoma, acute lymphoblastic leukemia | Sheba Medical Center | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHB-02-CD19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07503353 ↗ |
| Modality | Cell therapy | “a novel CAR-T treatment manufactured by the Advanced Biotherapy Center (ABC) at the Sheba Medical Center” NCT07503353 ↗ |
| Target | CD19 | “a gene that encodes a CAR which recognizes the CD19 antigen” NCT07503353 ↗ |